Diagnostic Testing of STDs Market, By Test Type (Chlamydia, Gonorrhea, Syphilis, HIV, HPV+pap smear, HSV, and Chancroid), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 10.4 billion in 2023 and is expected to exhibit a CAGR of 9.6 % during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The strategies adopted by key market players like approvals by regulatory bodies is expected to drive the global diagnostic testing of STDs market growth over the forecast period. For instance, on January 1, 2020, Vela Diagnostics Pte. Ltd., received the U.S. Food and Drug Administration (FDA) authorization for next generation sequencing test, Sentosa SQ HIV Genotyping assay for HIV drug resistance. Traditionally, healthcare providers used to monitor the efficacy of HIV antiviral drugs viral load tests.
Global Diagnostic Testing of STDs Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly, and had a serious negative impact on the economies, social behaviors, and healthcare worldwide.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdowns, several countries, such as India, China, Brazil, and others, faced problems with the transportation of drugs from one place to another.
COVID-19 negatively impacted the global diagnostic testing of STDs market due to decreased screening for STDs. For instance, according to an article published by Journal of The American Sexually Transmitted Disease Association in July 2021, a study was conducted to examine the electronic health record from 31 clinics. Data of STD testing encountered from patients aged 15-21 during eight months from the March 1, 2020 to October 31, 2020 was compared with eight month period in the previous year March 1, 2019 to October 31, 2019. It was found that during the pandemic, there were 3,476 STD testing encounters from 2,770 unique patients. During the pre-pandemic period, there were 4,699 STD testing encounters among 3,723 unique patients. However, the positivity rate of these tests was markedly higher for both chlamydia and gonorrhea. These higher test positivity rates suggested that during the COVID-19 pandemic symptomatic patients were likely being prioritized for testing, hence asymptomatic cases were undetected.
Global Diagnostic Testing of STDs Market: Key Developments
The increasing launch of products that can improve the efficacy of STD diagnostic methods are expected to drive the market growth.
For instance, on May 5, 2022, QIAGEN N.V., a Europe-based molecular diagnostic technology provider, announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and herpes simplex virus type 2 (HSV-2) received European conformity in vitro diagnostic devices (CE-IVD) certification for the European Union and other countries that accept this marking for use on NeuMoDx integrated in the Polymerase Chain Reaction (PCR) system.
Browse 17 Market Data Tables and 24 Figures spread through 160 Pages and in-depth TOC on Global Diagnostic Testing of STDs Market, By Test Type (Chlamydia, Gonorrhea, Syphilis, HIV, HPV+pap smear, HSV, and Chancroid), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/diagnostic-testing-of-stds-market-3917
Key Takeaways of the Global Diagnostic Testing of STDs Market:
- Global diagnostic testing of STDs market, is expected to exhibit a CAGR of 9.6 % during the forecast period. Awareness initiatives by government and non-government organizations is expected to accelerate the market growth. For instance, on March 15, 2021, National Alliance of State and Territorial AIDS Directors, a U.S.-based public health organization partnered with Building Healthy Online Communities and TakeMeHome, project with the goal of distributing up to 1 million free HIV testing kits on a free HIV and STD test kit home delivery program. The program has already distributed more than 5,000 HIV test kits in eight states around the U.S. and is now expanding to include test kits for syphilis, gonorrhea, and chlamydia.
- Among test type, the chlamydia segment is expected to dominate the global diagnostic testing of STDs market over the forecast period, owing to the launch of newer detection test kits. For instance, on March 30, 2021, the U.S. FDA allowed the use of Binx Health IO CT/NG Assay, a product of Binx Health Ltd, a U.S.-based molecular diagnostic company at point-of-care settings, such as in physician offices, community-based clinics, urgent care settings, outpatient health care facilities, and other patient care settings, operating under a Clinical Laboratory Improvement Amendments of 1988 (CLIA) Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation. This action is the result of the U.S. FDA granting a waiver under the CLIA for the Binx Health IO CT/NG Assay.
- Among region, North America is expected to be the dominant region in the global diagnostic testing of STDs market, owing to the increasing initiatives by the government to introduce newer cost effective rapid tests to detect STD infection. For instance, on November 15, 2021, World Health Organization recommended Simple-to-use dual HIV/syphilis Rapid Diagnostic Tests (RDTs), to eliminate mother-to-child transmission (EMTCT) of HIV and syphilis. A new partnership between Clinton Health Access Initiative (CHAI), global health organization committed to saving lives, reducing the burden of disease and strengthening health systems with MedAccess, social enterprise committed to improving health in low- and middle-income countries, and SD Biosensor, South Korea based global leader in diagnostic reagents will make these dual tests available for under US$ 1, marking it as the lowest priced WHO prequalified dual HIV/syphilis test available. This can increase rate of testing done for the syphilis and HIV which can drive the growth of the global diagnostic testing of STDs market.
- The major players operating in the global diagnostic testing of STDs market include Vela Diagnostics USA Inc., Roche Holdings AG, Alere, Inc., Becton Dickinson & Company, bioMerieux, Danaher Corporation (Beckman Coulter), Hologic, Inc., binx health, Chembio Diagnostics, Pinpoint Science Inc., and bioLytical Laboratories
